 |
|
TGen researchers find genetic markers to help fight diabetes
June 16, 2009Translational Genomics Research Institute (TGen) scientists have identified five genetic biomarkers that could help lead to improved treatments, with fewer side-effects, for patients with diabetes.
TGen Senior Investigator Dr. Johanna DiStefano presented the findings in New Orleans on June 6, 2009, at the 69th Scientific Sessions of the American Diabetes Association.
"We identified genetic variants that may predict how well someone will respond to the common anti-diabetes drug, Actos," said Dr. DiStefano, Director of TGen's Diabetes, Cardiovascular & Metabolic Diseases Division. "The implications of these findings include determining which patients will best respond to the drug for the prevention or treatment of diabetes. In addition, this work lays the foundation for personalized medicine for patients with this disease."
Personalized medicine involves the rapid application of laboratory discoveries to therapies, depending on the individual genetic make-up of each patient.
A TGen-led team, working with scientists from the University of Southern California's Keck School of Medicine, investigated why as many as 30-40 percent of diabetes patients treated with thiazolidinediones (TZDs), such as Actos, fail to respond to the drug with the expected improvement in insulin sensitivity.
TZDs are a class of insulin-sensitizing drugs used to treat type 2 diabetes mellitus (T2DM). TZDs are agonists for the nuclear receptor peroxisome proliferator-activated receptor-g (PPARG). Although the exact mechanism by which TZDs act is not yet known, data indicate that TZDs improve insulin sensitivity by direct and indirect effects on adipose tissue and muscle. TZD therapy can significantly lower diabetes incidence in at-risk subjects, suggesting this treatment may be an effective means to prevent the disease.
Previously, TGen and Keck investigators found that genetic variations in the PPARG gene were associated with TZD metabolism and the biological effects of TZD, and thereby contribute to the therapeutic response associated with TZD. However, these variants did not fully account for the non-response rate, suggesting that other variants may contribute to TZD response.
To identify other variants that predict response to TZDs, TGen researchers performed a genome-wide analysis of 115,352 single nucleotide polymorphisms, or SNPs (a DNA sequence variation within the more than 3 billion base pairs in the human genome). In addition, the scientists also systematically screened 28 key genes involved in TZD metabolism or PPARG-stimulated pathways.
Of the markers examined, DiStefano and her team identified five critical markers that may predict response to TZD mono-therapy. These markers include variants in a key drug metabolizing gene called cytochrome P450 3A4 and a PPARG-coactivator known as PPARGC1B. Other markers were located in genes associated with PPARG function and include the protein kinase MAP2K6, a potassium inwardly-rectifying channel called KCNJ16, and the farnesoid X receptor (NR1H4).
Together, these markers predicted both response to Actos therapy and improvement in insulin sensitivity in the patients taking the drug.
Dr. DiStefano said the next steps in this research will be to characterize the functional effects of the polymorphisms and assess the effect of these variants in other patients.
"This work may help treat the right people with the right drug, design better drugs that will effectively improve insulin sensitivity for more people, and possibly safeguard against adverse side reactions seen with some members of this drug class," she said. Importantly, these findings will enable us to dissect the pharmacogenetics of TZD response, which will expand our understanding of the genetic determinants of insulin resistance and its treatment, provide critical baseline information for the development and implementation of genetic screening into the therapeutic decision making process, and lay the foundation for "individualized medicine" for patients with T2D.
Other TGen scientists involved in the study were: Investigator Dr. David W. Craig and Research Associate Kimberly A. Yeatts.
Researchers from USC were: Drs. Anny H. Xiang, Thomas A. Buchanan and Richard M. Watanabe, and graduate student Mohamad T. Hassanein.
About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.
The Translational Genomics Research Institute (TGen)
Personalized medicine involves the rapid application of laboratory discoveries to therapies, depending on the individual genetic make-up of each patient.
A TGen-led team, working with scientists from the University of Southern California's Keck School of Medicine, investigated why as many as 30-40 percent of diabetes patients treated with thiazolidinediones (TZDs), such as Actos, fail to respond to the drug with the expected improvement in insulin sensitivity.
TZDs are a class of insulin-sensitizing drugs used to treat type 2 diabetes mellitus (T2DM). TZDs are agonists for the nuclear receptor peroxisome proliferator-activated receptor-g (PPARG). Although the exact mechanism by which TZDs act is not yet known, data indicate that TZDs improve insulin sensitivity by direct and indirect effects on adipose tissue and muscle. TZD therapy can significantly lower diabetes incidence in at-risk subjects, suggesting this treatment may be an effective means to prevent the disease.
Previously, TGen and Keck investigators found that genetic variations in the PPARG gene were associated with TZD metabolism and the biological effects of TZD, and thereby contribute to the therapeutic response associated with TZD. However, these variants did not fully account for the non-response rate, suggesting that other variants may contribute to TZD response.
To identify other variants that predict response to TZDs, TGen researchers performed a genome-wide analysis of 115,352 single nucleotide polymorphisms, or SNPs (a DNA sequence variation within the more than 3 billion base pairs in the human genome). In addition, the scientists also systematically screened 28 key genes involved in TZD metabolism or PPARG-stimulated pathways.
Of the markers examined, DiStefano and her team identified five critical markers that may predict response to TZD mono-therapy. These markers include variants in a key drug metabolizing gene called cytochrome P450 3A4 and a PPARG-coactivator known as PPARGC1B. Other markers were located in genes associated with PPARG function and include the protein kinase MAP2K6, a potassium inwardly-rectifying channel called KCNJ16, and the farnesoid X receptor (NR1H4).
Together, these markers predicted both response to Actos therapy and improvement in insulin sensitivity in the patients taking the drug.
Dr. DiStefano said the next steps in this research will be to characterize the functional effects of the polymorphisms and assess the effect of these variants in other patients.
"This work may help treat the right people with the right drug, design better drugs that will effectively improve insulin sensitivity for more people, and possibly safeguard against adverse side reactions seen with some members of this drug class," she said. Importantly, these findings will enable us to dissect the pharmacogenetics of TZD response, which will expand our understanding of the genetic determinants of insulin resistance and its treatment, provide critical baseline information for the development and implementation of genetic screening into the therapeutic decision making process, and lay the foundation for "individualized medicine" for patients with T2D.
Other TGen scientists involved in the study were: Investigator Dr. David W. Craig and Research Associate Kimberly A. Yeatts.
Researchers from USC were: Drs. Anny H. Xiang, Thomas A. Buchanan and Richard M. Watanabe, and graduate student Mohamad T. Hassanein.
About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.
The Translational Genomics Research Institute (TGen)
Diabetes Current Events and Diabetes News RSSStudy suggests dentists can identify patients at risk for fatal cardiovascular event
A new study indicates dentists can play a potentially life-saving role in health care by identifying patients at risk of fatal heart attacks and referring them to physicians for further evaluation.
Physical education key to improving health in low-income adolescents
School-based physical education plays a key role in curbing obesity and improving fitness among adolescents from low-income communities, according to a new study led by researchers at the University of California, San Francisco and UC Berkeley.
New class of molecules may help prevent fatal complication in patients with kidney disease
Researchers at the University of Maryland School of Medicine have made an important discovery about why potassium builds up to dangerous levels in the bloodstream, a relatively common medical problem that affects about eight percent of hospitalized patients.
AAP supports the IDF guideline on oral health for people with diabetes
New clinical guidelines released by the International Diabetes Foundation (IDF) emphasize the importance of periodontal health for people with diabetes.
American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding
The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible.
Study: Lap band surgery effective for morbidly obese children
A surgeon at Children's National Medical Center and his colleagues from New York University have found laparoscopic adjustable gastric banding (Lap band) to improve the health of morbidly obese adolescents.
Reduction in glycotoxins from heat-processing of foods reduces risk of chronic disease
Researchers from Mount Sinai School of Medicine report that cutting back on the consumption of processed and fried foods, which are high in toxins called Advanced Glycation End products (AGEs), can reduce inflammation and actually help restore the body's natural defenses regardless of age or health status.
Researchers discover links between city walkability and air pollution exposure
A new study compares neighborhoods' walkability (degree of ease for walking) with local levels of air pollution and finds that some neighborhoods might be good for walking, but have poor air quality.
Researchers identify the three killer indicators that are even worse than high cholesterol
Researchers at the University of Warwick have identified a particular combination of health problems that can double the risk of heart attack and cause a three-fold increase in the risk of mortality.
UM Scientists Create Fruit Fly Model to Help Unravel Genetics of Human Diabetes
As rates of obesity, diabetes, and related disorders have reached epidemic proportions in the US in recent years, scientists are working from many angles to pinpoint the causes and contributing factors involved in this public health crisis.
More Diabetes Current Events and Diabetes News Articles
 |
The First Year: Type 2 Diabetes: An Essential Guide for the Newly Diagnosed (First Year, The) by Gretchen Becker (Author), Allison B. Goldfine (Foreword) After Gretchen Becker was diagnosed with type 2 diabetes in 1996, she educated herself on every aspect of this chronic condition — by reading medical and scientific books and journals, talking with doctors and listening to her own body. In 2001, she marshaled everything she had learned as a "patient-expert" into the first edition of this book, which she has now completely updated and revised. The First Year®—Type 2 Diabetes uniquely guides you step-by-step through your first year with diabetes, walking you through everything you need to learn and do each day of your first week after diagnosis, each subsequent week of the first month, and each subsequent month of the crucial first year. In clear, concise, accessible language, Becker covers a wide range of practical, medical, and... |
 |
Diabetes Health Pack-Nature Made Multivitamin & Mineral Supplement, 60 Packets by Nature Made Nature Made® Diabetes Health Pack provides essential nutrients that may be lacking due to the strain diabetes can often put on the bodys health. Each pack provides a complete, full potency formulation of vitamins, minerals and alpha lipoic acid. |
 |
Diabetes For Dummies (For Dummies (Health & Fitness)) by Alan L. Rubin MD (Author) Covers the latest glucose meters and insulin treatments The straight facts on treating diabetes successfully and living a full life Want to know how to manage diabetes? Leading diabetes expert Dr. Alan Rubin gives you reassuring, authoritative guidance in putting together a state-of-the-art treatment program. You'll learn about all the advances in monitoring glucose, the latest medications, and how to develop a diet and exercise plan to stay healthy. You'll also see how to overcome insurance and on-the-job obstacles. Discover how to: Reduce your diabetes risk Understand the different types of diabetes Manage diabetes in children and the elderly Prevent long-term complications Get the support you need |
 |
The Official Pocket Guide to Diabetic Exchanges by American Diabetes Association (Author) Every day, every meal, millions and millions of people count on the world-famous Exchange Lists for Meal Planning to make sure they're choosing the right kinds of foods and portion sizes from the various food groups. Now people with diabetes can take the Exchange Lists with them to the grocery store or to restaurants with the Official Pocket Guide to Diabetic Exchanges. Measuring just 3.5" x 6", this little powerhouse is jam-packed with the exact same information found in the standard exchange lists, yet it fits conveniently into a purse or coat pocket. |
 |
Blood Sugar 101: What They Don't Tell You About Diabetes by Jenny Ruhl (Author) Based on the award winning Bloodsugar101.com web site, this book explains what peer-reviewed research published in top medical journals has to say about: What is a normal blood sugar? How does diabetes develop? What really causes diabetes? What blood sugar levels cause complications? Must you deteriorate? What diet is right for you? How can you make that diet work? What medications are safe? What supplements lower blood sugar? Written in clear and understandable language, this book provides all the tools needed to understand how blood sugar works and achieve blood sugar health. |
 |
OneTouch UltraMini Glucose Monitoring System, Silver Moon by OneTouch - LifeScan Black color only. |
 |
The 30-Day Diabetes Miracle: Lifestyle Center of America's Complete Program to Stop Diabetes, Restore Health,and Build Natural Vitality by Franklin House (Author), Stuart A. Seale (Author), Ian Blake Newman (Author) A revolutionary program for combating and reversing diabetes. Over the past ten years, Lifestyle Center of America has emerged as the center in the country that offers a proven-successful program to combat diabetes-and even reverse its adverse effects on the body. Now available in book form for the first time, LCA's program enables individuals to actually get to the root of their problems by teaching them the ways of lifestyle-change, the power of diet, activity, and stress management. It also shows how to: - Eliminate counterproductive habits - Adopt therapeutic and preventative nutritional changes - Overcome insulin resistance with a new lifestyle medicine paradigm - Achieve motivation and inspiration through pro-active healthcare coaching - Understand the extraordinary benefits of a... |
 |
Betty Crocker's Diabetes Cookbook: Everyday Meals, Easy as 1-2-3 by Betty Crocker Editors (Author) At last! This special cookbook puts flavor and choice back on the menu for people with diabetes and their families Betty Crocker, America's most trusted friend in the kitchen, has teamed up with the International Diabetes Center (IDC)--one of the leading medical centers--to create an indispensable source of easy-to-make recipes and up-to-the-minute food and nutrition information for the growing numbers of people who have diabetes, more than 15 million of them. Here is the first cookbook to include recipes featuring Carbohydrate Choices--the new, simplified approach to meal planning recommended by the American Diabetes Association. For people who find diet exchanges too hard, too limiting or too much work, this new method is a real breakthrough. Each of the book's 140 recipes... |
 |
Dr. Bernstein's Diabetes Solution: The Complete Guide to Achieving Normal Blood Sugars by Richard K. Bernstein (Author) The standard text on living with diabetes, newly revised and updated with all the latest scientific findings. Since its first publication in 1997, DR. BERNSTEIN'S DIABETES SOLUTION has become the treatment of choice in the medical field. In this revised and updated edition of his work, Dr. Bernstein provides an accessible, detailed guide to his revolutionary approach to normalizing blood sugars and thereby preventing or reversing long-term complications of diabetes. He offers the most up-to-date information on new products, medications, and supplements, and outlines a plan to reverse the obesity that underlies most cases of Type II diabetes. Dr. Bernstein discusses breakthrough science and potential cures, and has added information on the new insulins and insulin ... |
 |
Nature Made Diabetes Health Pack with Lutein , Multivitamin and Mineral Supplement, 30-Count Boxes (Pack of 2) by Nature Made Nature Made Diabetes Health Pack 30 Days |
| © 2009 BrightSurf.com |